PT  - JOURNAL ARTICLE
AU  - Pilling, Olivia A.
AU  - Grace, Cooper A.
AU  - Reis-Cunha, João L.
AU  - Berry, Alexander S. F.
AU  - Mitchell, Matthew W.
AU  - Yu, Jane A.
AU  - Malekshahi, Clara
AU  - Krespan, Elise
AU  - Go, Christina K.
AU  - Lombana, Cláudia
AU  - Song, Yun S.
AU  - Amorim, Camila F.
AU  - Lago, Alexsandro S.
AU  - Carvalho, Lucas P.
AU  - Carvalho, Edgar M.
AU  - Brisson, Dustin
AU  - Scott, Phillip
AU  - Jeffares, Daniel C.
AU  - Beiting, Daniel P.
TI  - Selective whole-genome amplification reveals population genetics of <em>Leishmania braziliensis</em> directly from patient skin biopsies
AID  - 10.1101/2022.09.06.22279552
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.09.06.22279552
4099  - http://medrxiv.org/content/early/2023/02/06/2022.09.06.22279552.short
4100  - http://medrxiv.org/content/early/2023/02/06/2022.09.06.22279552.full
AB  - In Brazil, Leishmania braziliensis is the main causative agent of the neglected tropical disease, cutaneous leishmaniasis (CL). CL presents on a spectrum of disease severity with a high rate of treatment failure. Yet the parasite factors that contribute to disease presentation and treatment outcome are not well understood, in part because successfully isolating and culturing parasites from patient lesions remains a major technical challenge. Here we describe the development of selective whole genome amplification (SWGA) for Leishmania and show that this method enables culture-independent analysis of parasite genomes obtained directly from primary patient skin samples, allowing us to circumvent artifacts associated with adaptation to culture. We show that SWGA can be applied to multiple Leishmania species residing in different host species, suggesting that this method is broadly useful in both experimental infection models and clinical studies. SWGA carried out directly on skin biopsies collected from patients in Corte de Pedra, Bahia, Brazil, showed extensive genomic diversity. Finally, as a proof-of-concept, we demonstrated that SWGA data can be integrated with published whole genome data from cultured parasite isolates to identify variants unique to specific geographic regions in Brazil where treatment failure rates are known to be high. SWGA provides a relatively simple method to generate Leishmania genomes directly from patient samples, unlocking the potential to link parasite genetics with host clinical phenotypes.AUTHOR SUMMARY Leishmania braziliensis is the main cause of cutaneous leishmaniasis in Brazil. Due to limitations in culturing, it is important to study the parasite in a culture-independent manner. We use selective whole genome amplification (SWGA) to explore parasite genomic diversity directly from patient biopsies. This method is inexpensive and can be broadly used to generate parasite genome sequence data sampled from different Leishmania species infecting different mammalian hosts. We found high diversity among the L. braziliensis genomes from Bahia, Brazil, which correlated with geographic location. By integrating these data with publicly available genome sequences from other studies spanning four countries in South America, we identified variants unique to Northeast Brazil that may be linked to high regional rates of treatment failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by grants from National Institute of Allergy and Infectious Diseases (5R01AI143790, 5T32AI007532-24, and 5R01AI149456-03). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Skin lesion biopsies were obtained with informed consent from cutaneous leishmaniasis (CL) patients seen at the Health Post of Corte de Pedra, Bahia, Brazil, in accordance with local ethical guidelines (Ethical Committee of the Federal University of Bahia Medical School, Salvador, Bahia, Brazil and the University of Pennsylvania Institutional Review Board).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw reads for all 18 SWGA genomes are available on the Sequence Read Archive (SRA) under accession number PRJNA875085.